| abstract |
The present invention is directed to synthetic cytoskeletal active compounds that are inhibitors of rho-related protein kinases. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention is further directed to a method for the prevention or treatment of diseases or conditions associated with cytoskeletal reconstruction. In one aspect of the invention, the method treats elevated intraocular pressure, such as primary open angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of formula I or II, wherein the amount is acted upon by leading to cell relaxation and alteration of cell-sublayer adhesion. Effective in affecting myosin interactions. |